Genitope sees $1 buy 8.1 million of its shares Wednesday
Genitope, the beleaguered Fremont biopharmaceutical that halted development of its experimental MyVax treatment for non-Hodgkin’s lymphoma last March after the Food and Drug Administration said at least one Read More → 